Article | December 1, 2021

Best Practices For Gaining Stakeholder Buy-In For Data Linkage In Clinical Trials

Source: Medidata AI

Data linkage lets sponsors link CTD with RWD at the patient level across current and completed trials—regardless of consent method—in a privacy-certified, CRO-agnostic manner while supporting multiple de-identification token schemas. It also lets sponsors track post-trial outcomes, enhance safety surveillance, and reduce burdensome follow-up visits. However, while the value of data linkage may be apparent to some, gaining patient, investigator, and internal organizational buy-in presents a barrier to evangelizing and championing data linkage.

To find out more about Medidata Solutions, visit their Clinical Leader page.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader